LifeStance Health Group (NASDAQ:LFST) Price Target Raised to $12.00

LifeStance Health Group (NASDAQ:LFST) had its price objective boosted by UBS Group from $10.00 to $12.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other equities research analysts also recently weighed in on the company. BMO Capital Markets began coverage on LifeStance Health Group in a report on Thursday, November 13th. They issued an “outperform” rating and a $8.00 target price on the stock. Wall Street Zen upgraded LifeStance Health Group from a “hold” rating to a “buy” rating in a research report on Sunday, February 8th. KeyCorp raised their price objective on LifeStance Health Group from $8.00 to $9.00 and gave the company an “overweight” rating in a research note on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of LifeStance Health Group in a research note on Monday, December 29th. Finally, Zacks Research cut shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, LifeStance Health Group presently has an average rating of “Moderate Buy” and a consensus price target of $9.67.

LifeStance Health Group Price Performance

LFST stock opened at $7.24 on Thursday. The company’s 50-day moving average price is $7.13 and its two-hundred day moving average price is $6.21. The firm has a market cap of $2.82 billion, a P/E ratio of 362.18 and a beta of 1.12. The company has a quick ratio of 1.58, a current ratio of 1.58 and a debt-to-equity ratio of 0.18. LifeStance Health Group has a 12 month low of $3.74 and a 12 month high of $8.30.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.02). The firm had revenue of $382.20 million for the quarter, compared to analyst estimates of $378.51 million. LifeStance Health Group had a return on equity of 0.66% and a net margin of 0.68%.The business’s revenue was up 17.4% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.01) EPS. On average, analysts anticipate that LifeStance Health Group will post -0.18 earnings per share for the current fiscal year.

LifeStance Health Group announced that its board has authorized a stock buyback program on Wednesday, February 25th that permits the company to buyback $100.00 million in outstanding shares. This buyback authorization permits the company to repurchase up to 3.6% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its stock is undervalued.

Insider Buying and Selling

In related news, Director Robert Bessler sold 119,942 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $7.04, for a total value of $844,391.68. Following the completion of the transaction, the director owned 1,318,983 shares in the company, valued at $9,285,640.32. This trade represents a 8.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Ann Varanakis sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $6.90, for a total transaction of $345,000.00. Following the sale, the insider directly owned 315,610 shares in the company, valued at $2,177,709. The trade was a 13.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 270,086 shares of company stock valued at $1,891,264. 3.20% of the stock is owned by company insiders.

Institutional Trading of LifeStance Health Group

Several institutional investors have recently modified their holdings of LFST. Larson Financial Group LLC increased its holdings in LifeStance Health Group by 19,952.6% in the fourth quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock valued at $27,000 after purchasing an additional 3,791 shares during the period. Bayesian Capital Management LP bought a new stake in shares of LifeStance Health Group in the 2nd quarter valued at about $52,000. Krane Funds Advisors LLC acquired a new stake in shares of LifeStance Health Group in the fourth quarter valued at about $71,000. Vanguard Personalized Indexing Management LLC bought a new position in shares of LifeStance Health Group during the third quarter worth about $72,000. Finally, Cibc World Markets Corp acquired a new position in shares of LifeStance Health Group in the fourth quarter worth approximately $77,000. Institutional investors own 85.50% of the company’s stock.

LifeStance Health Group News Summary

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Board authorizes a $100 million share repurchase (up to ~3.6% of shares), signaling management thinks the stock is undervalued and reducing float. LifeStance to Repurchase $100M
• Positive Sentiment: Multiple firms raised price targets and ratings (UBS to $12, Canaccord to $10, KeyCorp to $9), increasing visible upside and buy-side interest. Analyst Price Target Raises
• Positive Sentiment: Company set 2026 revenue target of $1.615B–$1.655B and highlighted progress on AI and EHR initiatives that can drive scale and margin expansion over time. 2026 Revenue Target & Initiatives
• Neutral Sentiment: Coverage roundup: several analysts reviewed the stock following the quarter; the market reaction depends on whether upgrades translate into sustained buy-side flows. 6 Analysts Assess LFST
• Negative Sentiment: Q4 EPS missed expectations (reported ~$0.03 vs. ~$0.06 expected) despite revenue beating estimates; EPS weakness and still-modest margins remain near-term headwinds. Q4 2025 Earnings Highlights
• Negative Sentiment: Selling stockholders filed a secondary offering of 25M shares (company not raising proceeds), creating potential supply/overhang that can cap near-term upside. Secondary Public Offering

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.